Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models.

[1]  Yun-Gen Xu,et al.  Synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing a cleavable moiety with anti-platelet activity. , 2012, European journal of medicinal chemistry.

[2]  B. Eriksson,et al.  Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: findings from four Phase 3 trials. , 2012, Thrombosis research.

[3]  E. D. Candia,et al.  Mechanisms of platelet activation by thrombin: A short history , 2012 .

[4]  T. Mavrakanas,et al.  The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. , 2011, Pharmacology & therapeutics.

[5]  S. Yusuf,et al.  Newly identified events in the RE-LY trial. , 2010, The New England journal of medicine.

[6]  A. Siegbahn,et al.  The influence of direct thrombin inhibitors on the formation of platelet-leukocyte aggregates and tissue factor expression. , 2010, Thrombosis research.

[7]  A. Clemens,et al.  Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[8]  S. Goldhaber,et al.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism. , 2009, The New England journal of medicine.

[9]  A. Lau,et al.  Antiplatelet and anticoagulant effects of Panax notoginseng: comparison of raw and steamed Panax notoginseng with Panax ginseng and Panax quinquefolium. , 2009, Journal of ethnopharmacology.

[10]  V. Laux,et al.  Direct inhibitors of coagulation proteins – the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? , 2009, Thrombosis and Haemostasis.

[11]  H. Bounameaux.  The novel anticoagulants: entering a new era. , 2009, Swiss medical weekly.

[12]  M. Franchini,et al.  Venous and arterial thrombosis: different sides of the same coin? , 2008, European journal of internal medicine.

[13]  P. Lam,et al.  Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies , 2008, Journal of thrombosis and haemostasis : JTH.

[14]  S. Frostick,et al.  Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial , 2007, Journal of thrombosis and haemostasis : JTH.

[15]  M. Ezekowitz,et al.  Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). , 2007, The American journal of cardiology.

[16]  E. Liu,et al.  Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats. , 2007, European journal of pharmacology.

[17]  J. Stassen,et al.  Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats , 2007, Thrombosis and Haemostasis.

[18]  J. Stassen,et al.  Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis , 2007, Journal of thrombosis and haemostasis : JTH.

[19]  T. Ruttmann.  Coagulation for the clinician. , 2006, South African journal of surgery. Suid-Afrikaanse tydskrif vir chirurgie.

[20]  D. Hoppensteadt,et al.  Monitoring the New Antithrombotic Drugs , 2004, Seminars in thrombosis and hemostasis.

[21]  M. Li,et al.  Specific inhibiting characteristics of tetramethylpyrazine, one of the active ingredients of the Chinese herbal medicine 'Chuanxiong,' on platelet thrombus formation under high shear rates. , 2001, Thrombosis research.

[22]  A. Vindigni,et al.  Platelet Glycoprotein Ibα Binds to Thrombin Anion-binding Exosite II Inducing Allosteric Changes in the Activity of Thrombin* , 2001, The Journal of Biological Chemistry.

[23]  B. Lindblad,et al.  Prevention of experimental venous thrombosis in rabbits with different low molecular weight heparins, dermatan sulphate and hirudin. , 1995, Haemostasis.

[24]  H. Ishihara,et al.  DX-9065a, a New Synthetic, Potent Anticoagulant and Selective Inhibitor for Factor Xa , 1994, Thrombosis and Haemostasis.

[25]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[26]  G. Born,et al.  The aggregation of blood platelets , 1963, The Journal of physiology.

[27]  M. Chiariello,et al.  Regular Article Activated platelets stimulate tissue factor expression in smooth muscle cells , 2003 .

[28]  M. Chiariello,et al.  Activated platelets stimulate tissue factor expression in smooth muscle cells. , 2003, Thrombosis research.